Keith G Rosauer

6531484, Mar 11, 2003

Oct 10, 2001

09/974643

Christopher A. Willoughby - Greenbrook NJ
Keith Rosauer - Matawan NJ
Kevin T. Chapman - Scotch Plains NJ
Sander G. Mills - Scotch Plains NJ
Min Shu - Wayne Brook NJ

Merck co., Inc. - Rahway NJ

A61K 3146

514304, 5142242, 5142305, 514249, 544 47, 544105, 544228, 544349, 546 23, 546125, 546126

Pyrrolidine compounds of Formula I: (wherein R , R , R , R , R , R , R , R , R , j, k, 1, m, and n are defined herein) are described. The compounds are modulators of CCR5 chemokine receptor activity. The compounds are useful, for example, in the prevention or treatment of infection by HIV and the treatment of AIDS, as compounds or pharmaceutically acceptable salts, or as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines. Methods of treating AIDS and methods of preventing or treating infection by HIV are also described.

7687534, Mar 30, 2010

Oct 2, 2007

11/906374

John E. Stelmach - Westfield NJ, US
Emma R. Parmee - Scotch Plains NJ, US
James R. Tata - Westfield NJ, US
Keith G. Rosauer - Laurence Harbor NJ, US
Ronald M. Kim - Summit NJ, US
Amy R. Bittner - Scotch Plains NJ, US
Jiang Chang - Westfield NJ, US
Christopher Joseph Sinz - Cranford NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/404
C07D 209/14

514415, 548511

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

7968589, Jun 28, 2011

Feb 9, 2010

12/702358

John E. Stelmach - Westfield NJ, US
Emma R. Parmee - Scotch Plains NJ, US
James R. Tata - Westfield NJ, US
Keith G. Rosauer - Laurence Harbor NJ, US
Ronald M. Kim - Summit NJ, US
Amy R. Bittner - Scotch Plains NJ, US
Jiang Chang - Westfield NJ, US
Christopher Joseph Sinz - Cranford NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A61K 31/404
C07D 209/10

514415, 548511

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

8318760, Nov 27, 2012

Mar 17, 2006

11/886136

John E. Stelmach - Westfield NJ, US
Keith G. Rosauer - Laurence Harbor NJ, US
Emma R. Parmee - Scotch Plains NJ, US
James R. Tata - Westfield NJ, US

Merck Sharp & Dohme Corp. - Rahway NJ

A01N 43/40
A01N 43/64
A01N 37/44
A61K 31/41
C07D 213/00
C07D 293/00
C07D 207/00
C07C 61/00
C07C 63/00
C07C 321/00
C07C 323/00

514277, 514359, 514381, 514563, 546 1, 548100, 548400, 562400, 562405, 562427

Substituted aryl and heteroaryl derivatives are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included.

20100004158, Jan 7, 2010

Sep 27, 2007

12/443746

John E. Stelmach - Westfield NJ, US
Emma R. Parmee - Scotch Plains NJ, US
James R. Tata - Westfield NJ, US
Keith G. Rosauer - Laurence Harbor NJ, US
Ronald M. Kim - Summit NJ, US
Amy R. Bittner - Scotch Plains NJ, US
Jiang Chang - Westfield NJ, US
Christopher Joseph Sinz - Cranford NJ, US

A61K 38/28
C07D 209/04
A61K 31/404
A61K 31/397
A61K 31/4985
A61K 31/426
A61P 3/10
A61P 3/04

514 3, 548511, 514415, 51421002, 514249, 514369

Glucagon receptor antagonist compounds are disclosed. The compounds are useful for treating type 2 diabetes and related conditions. Pharmaceutical compositions and methods of treatment are also included. (I)

20110218202, Sep 8, 2011

Nov 16, 2009

13/127334

Linda L. Brockunier - Orange NJ, US
Jian Guo - Scotch Plains NJ, US
Emma R. Parmee - Scotch Plains NJ, US
Subharekha Raghavan - Teaneck NJ, US
Keith Rosauer - Laurence Harbor NJ, US
Darby Schmidt - Arlington MA, US
John E. Stelmach - Westfield NJ, US

A61K 31/519
C07D 487/04
C07D 495/04
A61P 9/00
A61P 9/10
A61P 9/12
A61P 9/04
A61P 7/02
A61P 13/12
A61P 1/16
A61P 3/10

514248, 544280, 544236, 5142651

Compounds of Formula I are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of the Formula I, to their use for the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of the Formula I.

20130012511, Jan 10, 2013

Mar 22, 2011

13/636760

Darby Schmidt - Arlington MA, US
Subharekha Raghavan - Teaneck NJ, US
John Stelmach - Westfield NJ, US
Jian Guo - Scotch Plains NJ, US
Jonathan Groeper - Metuchen NJ, US
Linda Brockunier - Orange NJ, US
Keith Rosauer - Laurence Harbor NJ, US
Hong Shen - West Windsor NJ, US
Rui Liang - East Brunswick NJ, US

C07D 403/14
A61K 31/506
C07D 471/04
C07D 401/14
C07D 413/14
A61K 31/5377
C07D 417/14
C07D 403/04
A61P 9/00
A61P 9/10
A61P 9/12
A61P 9/04
A61P 7/02
A61P 11/00
A61P 15/00
A61P 11/06
A61P 13/12
A61P 3/10
A61P 1/16
A61P 9/08
A61P 7/10
A61P 3/00
A61P 3/06
C07D 487/04

5142345, 544236, 514248, 544328, 514256, 544324, 514275, 544296, 544122, 544295, 51425505

The invention relates to compounds having the structure of Formula (I) and pharmaceutically acceptable salts thereof, which are soluble guanylate cyclase activators. The compounds are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The compounds are useful for treatment or prevention of cardiovascular diseases, endothelial dysfunction, diastolic dysfunction, atherosclerosis, hypertension, pulmonary hypertension, angina pectoris, thromboses, restenosis, myocardial infarction, strokes, cardiac insufficiency, pulmonary hypertonia, erectile dysfunction, asthma bronchiale, chronic kidney insufficiency, diabetes, or cirrhosis of the liver.

20130072492, Mar 21, 2013

May 24, 2011

13/699046

Subharekha Raghavan - Teaneck NJ, US
John E. Stelmach - Westfield NJ, US
Cameron J. Smith - Lawrenceville NJ, US
Hong Li - Edison NJ, US
Alan Whitehead - Scotch Plains NJ, US
Sherman T. Waddell - Westfield NJ, US
Yi-Heng Chen - Whippany NJ, US
Shouwu Miao - Edison NJ, US
Olga A. Ornoski - Teaneck NJ, US
Joie Garfunkle - Metuchen NJ, US
Xibin Liao - Edison NJ, US
Jiang Chang - Westfield NJ, US
Xiaoqing Han - Edison NJ, US
Jian Guo - Scotch Plains NJ, US
Jonathan A. Groeper - Metuchen NJ, US
Linda L. Brockunier - Orange NJ, US
Keith Rosauer - New Hampton IA, US
Emma R. Parmee - Doylestown PA, US

C07D 487/04
C07D 495/04
A61K 31/5025
A61P 9/00
A61P 9/10
A61P 9/12
A61P 9/04
A61P 7/02
A61P 15/00
A61P 11/06
A61P 13/12
A61P 3/10
A61P 1/16
A61P 9/08
A61P 3/00
A61P 3/06
A61P 7/10
A61K 31/519

514248, 544280, 5142651, 544236, 51425505, 544281, 5142591

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate (“cGMP”) and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof.